• Angiotensin (1-7): Evidence, Biology and Limits

  2026-10-07

  Angiotensin (1-7), or Asp-Arg-Val-Tyr-Ile-His-Pro, is an endogenous renin–angiotensin system peptide commonly studied through Mas receptor biology. This overview compares its proposed signaling, fibrosis, inflammation, metabolic, neurological and translational applications with a 2025 study reporting that several angiotensin peptides enhance SARS-CoV-2 spike-protein receptor binding. The evidence remains mechanistic and model-dependent, with no basis for treating these findings as proof of clinical benefit or disease causation.

• Bestatin Hydrochloride: From Enzymes to Translation

  2026-10-07

  Bestatin hydrochloride, also known as Ubenimex, is best understood as a mechanistic probe of aminopeptidase-dependent peptide processing rather than as a single-pathway solution. This article connects classic neurobiology evidence with translational frameworks for angiogenesis inhibition, tumor growth and invasion research, and cancer research while emphasizing selectivity, provenance, and evidence boundaries.

• Demethyleneberberine, Senescence, and NSCLC

  2026-10-06

  A 2021 Phytomedicine study identified Demethyleneberberine as an inhibitor of NSCLC growth that links cell-cycle arrest and cellular senescence to the c-Myc/HIF-1α axis. The findings provide a mechanistic basis for further non-small cell lung cancer research, while remaining limited to preclinical cell and tumor-model evidence.

• Fumagillin Against Azumiobodo hoyamushi: Study Findings

  2026-10-06

  Park and colleagues evaluated 20 compounds against Azumiobodo hoyamushi, linking in vitro parasite-killing activity with a limited in vivo assessment in infected ascidians. Fumagillin showed moderate in vitro activity, whereas formalin and chlorine dioxide produced the clearest reported reductions in parasite burden during the host-level comparison.

• Lenalidomide and DOT1L in Myeloma Research

  2026-10-05

  Lenalidomide, also known as CC-5013, is an immunomodulatory drug central to multiple myeloma research. A 2025 Cancer Letters study provides preclinical evidence that DOT1L inhibition can activate innate immune programs and enhance lenalidomide-associated effects in myeloma models. This overview examines the findings, proposed biology, conceptual applications, evidence strength, and limits on translation to patient care.

• Fumagillin Beyond the Product Page

  2026-10-05

  Fumagillin sits at the intersection of angiogenesis biology and antiparasitic pharmacology. This thought-leadership review separates mechanism, comparative evidence, translational relevance, and model-specific limitations so researchers can interpret the compound without overstating what any single study demonstrates.

• Thrombin B Chain Fragment: Evidence and Research Context

  2026-10-04

  This overview distinguishes the established biology of full-length Thrombin from the much narrower evidence available for the Coagulation Factor II (Thrombin) B Chain Fragment [Homo sapiens]. It reviews conceptual research applications, compares the supplied product information with findings from a SARS-CoV-2 protease study, and explains why catalog purity and sequence data do not establish biological activity.

• Tubastatin A in Post-Resuscitation Myocardial Injury

  2026-10-02

  A porcine cardiac arrest study reports that Tubastatin A reduced post-resuscitation myocardial dysfunction, cardiac injury biomarkers, inflammatory cytokines, and markers of GSDME-associated pyroptosis and MLKL-associated necroptosis. The work is notable for examining two inflammatory cell-death programs in a large-animal ischemia–reperfusion model, while its short follow-up and non-genetic design mean that the proposed mechanism remains suggestive rather than proven.

• Losartan B1072 for Reliable Cell Assays

  2026-10-01

  This scenario-based guide shows how Losartan, SKU B1072, can improve interpretation and handling of cell viability, proliferation, and cytotoxicity experiments involving AT1 receptor signaling. It combines product-specific solubility and stability data with recent evidence linking AT1R biology to vascular and podocyte models.

• MDM1, p53, and CRC Chemoradiotherapy Sensitivity

  2026-10-01

  The reference study identifies MDM1 as a mechanistic determinant of colorectal cancer response to chemoradiotherapy, connecting MDM1 expression with YBX1-dependent TP53 regulation and apoptosis. Its genetic, transcriptomic, cellular, and xenograft evidence supports MDM1 as a candidate predictive biomarker and suggests that restoring apoptotic competence may help address treatment resistance.

• Anti Reverse Cap Analog: From Cap to Translation

  2026-09-30

  A translational guide to how Anti Reverse Cap Analog (ARCA), 3´-O-Me-m7G(5')ppp(5')G, can help researchers control mRNA cap orientation, translation initiation, and experimental reproducibility while interpreting emerging mRNA delivery studies with appropriate caution.

• BAY-826 in Tie-2–PEDF Retinal Assays

  2026-09-30

  BAY-826 is a potent small molecule inhibitor for dissecting angiopoietin-linked neurovascular signaling. This guide translates Müller cell and PEDF findings into practical assay design, controls, handling decisions, and interpretation limits.

• Lisinopril Dihydrate: From ACE Inhibition to Translation

  2026-09-29

  Lisinopril dihydrate offers a mechanistically interpretable way to interrogate the renin–angiotensin system across hypertension research, heart failure research, acute myocardial infarction research, and diabetic nephropathy models. This thought-leadership guide connects nanomolar ACE inhibition with assay design, comparator selection, and translational decision-making.

• LMO2–LDB1 Signaling in Acute Myeloid Leukemia

  2026-09-29

  The reference study defines an LMO2/LDB1 protein complex as a functional driver of acute myeloid leukemia (AML), rather than treating LMO2 only as a prognostic marker. By combining genetic perturbation, protein-interaction analysis, rescue experiments, and transcriptomic and chromatin profiling, it connects this complex to AML cell survival, proliferation, colony formation, and apoptosis-related gene regulation.

• Angiotensin 1/2 (1-6): Assay Strategy

  2026-09-28

  Explore how Angiotensin 1/2 (1-6), the Asp-Arg-Val-Tyr-Ile-His hexapeptide, can be used to design more discriminating renin-angiotensin system and receptor-binding studies. This guide translates recent spike–AXL binding findings into practical assay controls while separating biochemical evidence from physiological interpretation.

7787 records 1/520 page Next 12345 下5页 Last page